SRSF9 Protein
Overview
SRSF9, also known as Serine/Arginine-Rich Splicing Factor 9 or SRp30c, is a member of the SR (serine/arginine-rich) protein family of splicing regulators. This 30 kDa RNA-binding protein is encoded by the SRSF9 gene and is ubiquitously expressed across human tissues, with particularly high levels in the central nervous system. SRSF9 functions primarily as a splicing factor that regulates alternative splicing patterns through interaction with pre-messenger RNA (pre-mRNA) and the spliceosome machinery. The protein contains characteristic RS (arginine-serine) domains that mediate protein-protein interactions and promote nuclear localization, along with RNA recognition motifs (RRMs) that enable sequence-specific RNA binding. Due to its role in regulating the splicing of disease-associated transcripts, SRSF9 has emerged as an important factor in neurodegenerative disease pathogenesis.
Function/Biology
SRSF9 operates as a key component of the splicing regulatory network that determines which exons are included or excluded during pre-mRNA processing. At the molecular level, SRSF9 recognizes specific sequences within pre-mRNA substrates through its two RNA recognition motifs and recruits the spliceosomal machinery to promote exon inclusion or exclusion in a context-dependent manner. The protein's RS-rich domain facilitates recruitment of the U1 and U2 snRNPs (small nuclear ribonucleoproteins), core components of the spliceosome, to regulatory RNA sequences including splicing enhancer and silencer elements.
...SRSF9 Protein
Overview
SRSF9, also known as Serine/Arginine-Rich Splicing Factor 9 or SRp30c, is a member of the SR (serine/arginine-rich) protein family of splicing regulators. This 30 kDa RNA-binding protein is encoded by the SRSF9 gene and is ubiquitously expressed across human tissues, with particularly high levels in the central nervous system. SRSF9 functions primarily as a splicing factor that regulates alternative splicing patterns through interaction with pre-messenger RNA (pre-mRNA) and the spliceosome machinery. The protein contains characteristic RS (arginine-serine) domains that mediate protein-protein interactions and promote nuclear localization, along with RNA recognition motifs (RRMs) that enable sequence-specific RNA binding. Due to its role in regulating the splicing of disease-associated transcripts, SRSF9 has emerged as an important factor in neurodegenerative disease pathogenesis.
Function/Biology
SRSF9 operates as a key component of the splicing regulatory network that determines which exons are included or excluded during pre-mRNA processing. At the molecular level, SRSF9 recognizes specific sequences within pre-mRNA substrates through its two RNA recognition motifs and recruits the spliceosomal machinery to promote exon inclusion or exclusion in a context-dependent manner. The protein's RS-rich domain facilitates recruitment of the U1 and U2 snRNPs (small nuclear ribonucleoproteins), core components of the spliceosome, to regulatory RNA sequences including splicing enhancer and silencer elements.
Beyond splicing, SRSF9 participates in other aspects of RNA metabolism. The protein can modulate mRNA export from the nucleus through interactions with nuclear export machinery, influence mRNA translation efficiency, and contribute to mRNA stability and localization within cells. These pleiotropic functions make SRSF9 a central regulator of gene expression at multiple post-transcriptional levels. SRSF9 can form homo-oligomers and heteromeric complexes with other SR proteins and splicing regulators, allowing for combinatorial control of splicing outcomes.
Role in Neurodegeneration
SRSF9 dysregulation has been implicated in multiple neurodegenerative diseases, most notably amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). In ALS, mutations and altered expression levels of SRSF9 can affect splicing of critical motor neuron-specific transcripts. The protein regulates splicing of the survival motor neuron (SMN) gene, whose reduced expression is pathogenic in SMA. Additionally, SRSF9 controls splicing of TAU pre-mRNA, producing different tau isoforms with varying propensities to aggregate and contribute to tauopathies including Alzheimer's disease and progressive supranuclear palsy.
SRSF9 also regulates splicing of other neurodegeneration-associated transcripts including FUS (fused in sarcoma), which when mutated causes familial ALS, and genes involved in autophagy pathways critical for clearing protein aggregates. Aberrant SRSF9 activity or expression can therefore compromise multiple protective cellular mechanisms in neurons, including protein quality control and mitochondrial function.
Molecular Mechanisms
The neuropathological mechanisms involving SRSF9 dysfunction center on altered splicing patterns of essential neuronal transcripts. Dysregulation can result from direct mutations affecting the SRSF9 sequence, changes in SRSF9 phosphorylation status (which modulates its splicing activity), sequestration by disease proteins like TDP-43 or FUS aggregates, or altered expression levels. These perturbations shift the balance of splicing toward pathogenic isoforms. For example, reduced SRSF9 activity in ALS increases production of cryptic exon-containing transcripts and non-functional protein variants lacking essential functional domains.
SRSF9 function is regulated through dynamic phosphorylation by kinases including SRPK1 and CLK1/4, which modulate its subcellular localization and splicing activity. In neurodegenerative contexts, altered kinase activity or protein phosphatase function can abnormally regulate SRSF9 phosphorylation, impairing its biological function.
Clinical/Research Significance
SRSF9 represents a therapeutic target in multiple neurodegenerative diseases. Modulating SRSF9 activity or expression through antisense oligonucleotides, small molecules, or genetic approaches offers potential to correct pathogenic splicing patterns. Research efforts focus on developing SRSF9-targeting therapies to promote production of protective transcript isoforms, particularly for SMN in SMA and pathogenic tau isoforms in tauopathies. Understanding SRSF9 regulation also provides insights into broader splicing dysregulation mechanisms in neurodegeneration.
Related SR proteins include SRSF1, SRSF3, SRSF6, and SRSF7, which perform overlapping splicing regulatory functions. Associated proteins include kinases CLK1